UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 20-1968197 (State or other jurisdiction ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2018 Results Earnings Conference Call March 8, 2019 8:00 AM ET Company Participants Joshua Reed - Chief Financial Officer Todd Brady - Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citigroup Adam Walsh - Stifel Esther Hong - Janney Montgomery Scott I-Eh Jen - Laidlaw & Company Matthew Cross - JonesTrading Operator Good morning and welcome to Aldeyra Therapeutics Fourth Quarter and Full Year 2018 Financial Results Conference Call. All ...